Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Multiple Myeloma 10Recurrence 4Neurofibrosarcoma 2Myeloproliferative Disorders 2Lymphoma, Large B-Cell, Diffuse 2Leukemia, Myeloid, Acute 2Endometrial Neoplasms 2Wilms Tumor 1Vascular Neoplasms 1Uterine Neoplasms 1Uterine Diseases 1Solitary Fibrous Tumors 1Smooth Muscle Tumor 1Sarcoma, Clear Cell 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Rhabdoid Tumor 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Osteosarcoma 1Nerve Sheath Neoplasms 1Neoplasms, Adipose Tissue 1Neoplasms by Site 1Neoplasms 1Myoepithelioma 1Lymphoma, Non-Hodgkin 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma, B-Cell 1Lymphoma 1Liposarcoma, Myxoid 1

Interventions

asciminib 15Cyclophosphamide 12fludarabine phosphate 10Mycophenolic Acid 9fludarabine 8nilotinib 7Whole-Body Irradiation 7Imatinib Mesylate 6Dasatinib 6Tacrolimus 5Sirolimus 5Cyclosporine 5venetoclax 4bosutinib 4Melphalan 4Granulocyte Colony-Stimulating Factor 4ponatinib 3Thiotepa 3Stem Cell Transplantation 3Peripheral Blood Stem Cell Transplantation 3Cyclosporins 3Busulfan 3thymoglobulin 2ruxolitinib 2Specimen Handling 2Mesna 2Magnetic Resonance Spectroscopy 2Filgrastim 2Blood Component Removal 2treosulfan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Myelogenous, Chronic, BCR-ABL Positive × selinexor × 90 days × Clear all
NCT02091245 2026-05-29

Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML

Dana-Farber Cancer Institute

Phase 1 Active not recruiting
16 enrolled
LymphoidMyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡